TNSN07078A1 - Conjugues d'hormone de croissance humaine avec un polyethyleneglycol ramifie avec du glycerol, procede pour leur preparation et methodes pour leur utilisation - Google Patents
Conjugues d'hormone de croissance humaine avec un polyethyleneglycol ramifie avec du glycerol, procede pour leur preparation et methodes pour leur utilisationInfo
- Publication number
- TNSN07078A1 TNSN07078A1 TNP2007000078A TNSN07078A TNSN07078A1 TN SN07078 A1 TNSN07078 A1 TN SN07078A1 TN P2007000078 A TNP2007000078 A TN P2007000078A TN SN07078 A TNSN07078 A TN SN07078A TN SN07078 A1 TNSN07078 A1 TN SN07078A1
- Authority
- TN
- Tunisia
- Prior art keywords
- leu
- ser
- glu
- gln
- phe
- Prior art date
Links
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 title abstract 6
- 102000002265 Human Growth Hormone Human genes 0.000 title abstract 6
- 108010000521 Human Growth Hormone Proteins 0.000 title abstract 6
- 239000000854 Human Growth Hormone Substances 0.000 title abstract 6
- 238000000034 method Methods 0.000 title abstract 3
- 239000002202 Polyethylene glycol Substances 0.000 title 1
- 229920001223 polyethylene glycol Polymers 0.000 title 1
- KOSRFJWDECSPRO-UHFFFAOYSA-N alpha-L-glutamyl-L-glutamic acid Natural products OC(=O)CCC(N)C(=O)NC(CCC(O)=O)C(O)=O KOSRFJWDECSPRO-UHFFFAOYSA-N 0.000 abstract 2
- 230000006320 pegylation Effects 0.000 abstract 2
- XSTZMVAYYCJTNR-DCAQKATOSA-N Ala-Met-Leu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(C)C)C(O)=O XSTZMVAYYCJTNR-DCAQKATOSA-N 0.000 abstract 1
- OTZMRMHZCMZOJZ-SRVKXCTJSA-N Arg-Leu-Glu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O OTZMRMHZCMZOJZ-SRVKXCTJSA-N 0.000 abstract 1
- WMEVEPXNCMKNGH-IHRRRGAJSA-N Arg-Leu-His Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N WMEVEPXNCMKNGH-IHRRRGAJSA-N 0.000 abstract 1
- HBUJSDCLZCXXCW-YDHLFZDLSA-N Asn-Val-Tyr Chemical compound NC(=O)C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 HBUJSDCLZCXXCW-YDHLFZDLSA-N 0.000 abstract 1
- DWOGMPWRQQWPPF-GUBZILKMSA-N Asp-Leu-Glu Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O DWOGMPWRQQWPPF-GUBZILKMSA-N 0.000 abstract 1
- UJGRZQYSNYTCAX-SRVKXCTJSA-N Asp-Leu-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC(O)=O UJGRZQYSNYTCAX-SRVKXCTJSA-N 0.000 abstract 1
- WWOYXVBGHAHQBG-FXQIFTODSA-N Asp-Met-Asp Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(O)=O WWOYXVBGHAHQBG-FXQIFTODSA-N 0.000 abstract 1
- 208000012239 Developmental disease Diseases 0.000 abstract 1
- PCKOTDPDHIBGRW-CIUDSAMLSA-N Gln-Cys-Arg Chemical compound C(C[C@@H](C(=O)O)NC(=O)[C@H](CS)NC(=O)[C@H](CCC(=O)N)N)CN=C(N)N PCKOTDPDHIBGRW-CIUDSAMLSA-N 0.000 abstract 1
- MADFVRSKEIEZHZ-DCAQKATOSA-N Gln-Gln-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCC(=O)N)N MADFVRSKEIEZHZ-DCAQKATOSA-N 0.000 abstract 1
- DQLVHRFFBQOWFL-JYJNAYRXSA-N Gln-Lys-Tyr Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(=O)N)N)O DQLVHRFFBQOWFL-JYJNAYRXSA-N 0.000 abstract 1
- LPIKVBWNNVFHCQ-GUBZILKMSA-N Gln-Ser-Leu Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O LPIKVBWNNVFHCQ-GUBZILKMSA-N 0.000 abstract 1
- JDUKCSSHWNIQQZ-IHRRRGAJSA-N Glu-Phe-Glu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O JDUKCSSHWNIQQZ-IHRRRGAJSA-N 0.000 abstract 1
- NNQDRRUXFJYCCJ-NHCYSSNCSA-N Glu-Pro-Val Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(O)=O NNQDRRUXFJYCCJ-NHCYSSNCSA-N 0.000 abstract 1
- BPQYBFAXRGMGGY-LAEOZQHASA-N Gly-Gln-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)CN BPQYBFAXRGMGGY-LAEOZQHASA-N 0.000 abstract 1
- LBDXVCBAJJNJNN-WHFBIAKZSA-N Gly-Ser-Cys Chemical compound NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(O)=O LBDXVCBAJJNJNN-WHFBIAKZSA-N 0.000 abstract 1
- OMNVOTCFQQLEQU-CIUDSAMLSA-N His-Asn-Asp Chemical compound C1=C(NC=N1)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC(=O)O)C(=O)O)N OMNVOTCFQQLEQU-CIUDSAMLSA-N 0.000 abstract 1
- JRYQSFOFUFXPTB-RWRJDSDZSA-N Ile-Gln-Thr Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)N JRYQSFOFUFXPTB-RWRJDSDZSA-N 0.000 abstract 1
- HHSJMSCOLJVTCX-ZDLURKLDSA-N L-Glutaminyl-L-threonine Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@@H](N)CCC(N)=O HHSJMSCOLJVTCX-ZDLURKLDSA-N 0.000 abstract 1
- UILIPCLTHRPCRB-XUXIUFHCSA-N Leu-Arg-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)N UILIPCLTHRPCRB-XUXIUFHCSA-N 0.000 abstract 1
- YORLGJINWYYIMX-KKUMJFAQSA-N Leu-Cys-Phe Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O YORLGJINWYYIMX-KKUMJFAQSA-N 0.000 abstract 1
- QVFGXCVIXXBFHO-AVGNSLFASA-N Leu-Glu-Leu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O QVFGXCVIXXBFHO-AVGNSLFASA-N 0.000 abstract 1
- WXUOJXIGOPMDJM-SRVKXCTJSA-N Leu-Lys-Asn Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(O)=O WXUOJXIGOPMDJM-SRVKXCTJSA-N 0.000 abstract 1
- FLNPJLDPGMLWAU-UWVGGRQHSA-N Leu-Met-Gly Chemical compound OC(=O)CNC(=O)[C@H](CCSC)NC(=O)[C@@H](N)CC(C)C FLNPJLDPGMLWAU-UWVGGRQHSA-N 0.000 abstract 1
- TWPCWKVOZDUYAA-KKUMJFAQSA-N Lys-Phe-Asp Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(O)=O)C(O)=O TWPCWKVOZDUYAA-KKUMJFAQSA-N 0.000 abstract 1
- UGCIQUYEJIEHKX-GVXVVHGQSA-N Lys-Val-Glu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O UGCIQUYEJIEHKX-GVXVVHGQSA-N 0.000 abstract 1
- WSXKXSBOJXEZDV-DLOVCJGASA-N Phe-Ala-Asn Chemical compound NC(=O)C[C@@H](C([O-])=O)NC(=O)[C@H](C)NC(=O)[C@@H]([NH3+])CC1=CC=CC=C1 WSXKXSBOJXEZDV-DLOVCJGASA-N 0.000 abstract 1
- HWMGTNOVUDIKRE-UWVGGRQHSA-N Phe-Asp Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 HWMGTNOVUDIKRE-UWVGGRQHSA-N 0.000 abstract 1
- SWZKMTDPQXLQRD-XVSYOHENSA-N Phe-Asp-Thr Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O SWZKMTDPQXLQRD-XVSYOHENSA-N 0.000 abstract 1
- MJAYDXWQQUOURZ-JYJNAYRXSA-N Phe-Lys-Gln Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(O)=O MJAYDXWQQUOURZ-JYJNAYRXSA-N 0.000 abstract 1
- XOHJOMKCRLHGCY-UNQGMJICSA-N Phe-Pro-Thr Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(O)=O XOHJOMKCRLHGCY-UNQGMJICSA-N 0.000 abstract 1
- ZSKJPKFTPQCPIH-RCWTZXSCSA-N Pro-Arg-Thr Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(O)=O ZSKJPKFTPQCPIH-RCWTZXSCSA-N 0.000 abstract 1
- XQPHBAKJJJZOBX-SRVKXCTJSA-N Pro-Lys-Glu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(O)=O XQPHBAKJJJZOBX-SRVKXCTJSA-N 0.000 abstract 1
- GOMUXSCOIWIJFP-GUBZILKMSA-N Pro-Ser-Arg Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O GOMUXSCOIWIJFP-GUBZILKMSA-N 0.000 abstract 1
- RZEQTVHJZCIUBT-WDSKDSINSA-N Ser-Arg Chemical compound OC[C@H](N)C(=O)N[C@H](C(O)=O)CCCNC(N)=N RZEQTVHJZCIUBT-WDSKDSINSA-N 0.000 abstract 1
- VQBCMLMPEWPUTB-ACZMJKKPSA-N Ser-Glu-Ser Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O VQBCMLMPEWPUTB-ACZMJKKPSA-N 0.000 abstract 1
- VMLONWHIORGALA-SRVKXCTJSA-N Ser-Leu-Leu Chemical compound CC(C)C[C@@H](C([O-])=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]([NH3+])CO VMLONWHIORGALA-SRVKXCTJSA-N 0.000 abstract 1
- IXZHZUGGKLRHJD-DCAQKATOSA-N Ser-Leu-Val Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(O)=O IXZHZUGGKLRHJD-DCAQKATOSA-N 0.000 abstract 1
- FZEUTKVQGMVGHW-AVGNSLFASA-N Ser-Phe-Gln Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCC(N)=O)C(O)=O FZEUTKVQGMVGHW-AVGNSLFASA-N 0.000 abstract 1
- FVFUOQIYDPAIJR-XIRDDKMYSA-N Ser-Trp-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)NC(=O)[C@H](CO)N FVFUOQIYDPAIJR-XIRDDKMYSA-N 0.000 abstract 1
- BEBVVQPDSHHWQL-NRPADANISA-N Ser-Val-Glu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O BEBVVQPDSHHWQL-NRPADANISA-N 0.000 abstract 1
- OJRNZRROAIAHDL-LKXGYXEUSA-N Thr-Asn-Ser Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(O)=O OJRNZRROAIAHDL-LKXGYXEUSA-N 0.000 abstract 1
- WNQJTLATMXYSEL-OEAJRASXSA-N Thr-Phe-Leu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(O)=O WNQJTLATMXYSEL-OEAJRASXSA-N 0.000 abstract 1
- CYCGARJWIQWPQM-YJRXYDGGSA-N Thr-Tyr-Ser Chemical compound C[C@@H](O)[C@H]([NH3+])C(=O)N[C@H](C(=O)N[C@@H](CO)C([O-])=O)CC1=CC=C(O)C=C1 CYCGARJWIQWPQM-YJRXYDGGSA-N 0.000 abstract 1
- CNLKDWSAORJEMW-KWQFWETISA-N Tyr-Gly-Ala Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)NCC(=O)N[C@@H](C)C(O)=O CNLKDWSAORJEMW-KWQFWETISA-N 0.000 abstract 1
- KCPFDGNYAMKZQP-KBPBESRZSA-N Tyr-Gly-Leu Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)NCC(=O)N[C@@H](CC(C)C)C(O)=O KCPFDGNYAMKZQP-KBPBESRZSA-N 0.000 abstract 1
- DJSYPCWZPNHQQE-FHWLQOOXSA-N Tyr-Tyr-Gln Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCC(N)=O)C(O)=O)C1=CC=C(O)C=C1 DJSYPCWZPNHQQE-FHWLQOOXSA-N 0.000 abstract 1
- 108010052670 arginyl-glutamyl-glutamic acid Proteins 0.000 abstract 1
- 108010040443 aspartyl-aspartic acid Proteins 0.000 abstract 1
- 108010092854 aspartyllysine Proteins 0.000 abstract 1
- 108010042598 glutamyl-aspartyl-glycine Proteins 0.000 abstract 1
- 108010055341 glutamyl-glutamic acid Proteins 0.000 abstract 1
- 208000037824 growth disorder Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 108010051242 phenylalanylserine Proteins 0.000 abstract 1
- 108010077112 prolyl-proline Proteins 0.000 abstract 1
- 108010048818 seryl-histidine Proteins 0.000 abstract 1
- 108010061238 threonyl-glycine Proteins 0.000 abstract 1
- 108010015666 tryptophyl-leucyl-glutamic acid Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH], i.e. somatotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Reproductive Health (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Gynecology & Obstetrics (AREA)
- Psychiatry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Pregnancy & Childbirth (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US60594504P | 2004-08-31 | 2004-08-31 | |
PCT/IB2005/002939 WO2006024953A2 (en) | 2004-08-31 | 2005-08-25 | Glycerol branched polyethylene glycol human growth hormone conjugates, process for their preparation, and methods of use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
TNSN07078A1 true TNSN07078A1 (fr) | 2008-06-02 |
Family
ID=35708806
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TNP2007000078A TNSN07078A1 (fr) | 2004-08-31 | 2007-02-27 | Conjugues d'hormone de croissance humaine avec un polyethyleneglycol ramifie avec du glycerol, procede pour leur preparation et methodes pour leur utilisation |
Country Status (24)
Country | Link |
---|---|
EP (1) | EP1789092A2 (ru) |
JP (1) | JP2008511610A (ru) |
KR (1) | KR20070042567A (ru) |
CN (1) | CN101010105A (ru) |
AP (1) | AP2007003919A0 (ru) |
AR (1) | AR050851A1 (ru) |
AU (1) | AU2005278903A1 (ru) |
BR (1) | BRPI0515118A (ru) |
CA (1) | CA2577999A1 (ru) |
CR (1) | CR8942A (ru) |
EA (1) | EA200700380A1 (ru) |
EC (1) | ECSP077281A (ru) |
GT (1) | GT200500235A (ru) |
IL (1) | IL181085A0 (ru) |
MA (1) | MA28908B1 (ru) |
MX (1) | MX2007002441A (ru) |
NL (1) | NL1029828C2 (ru) |
NO (1) | NO20071322L (ru) |
PE (1) | PE20060654A1 (ru) |
TN (1) | TNSN07078A1 (ru) |
TW (1) | TW200621291A (ru) |
UY (1) | UY29088A1 (ru) |
WO (1) | WO2006024953A2 (ru) |
ZA (1) | ZA200701802B (ru) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69838552T2 (de) | 1997-07-14 | 2008-05-21 | Bolder Biotechnology, Inc., Louisville | Derivate des wachstumshormons und verwandte proteine |
US7495087B2 (en) | 1997-07-14 | 2009-02-24 | Bolder Biotechnology, Inc. | Cysteine muteins in the C-D loop of human interleukin-11 |
EP2305804B1 (en) | 1999-01-14 | 2015-05-06 | Bolder Biotechnology, Inc. | MonoPEGylated human growth hormone |
US7855279B2 (en) | 2005-09-27 | 2010-12-21 | Amunix Operating, Inc. | Unstructured recombinant polymers and uses thereof |
EP1834963A1 (en) * | 2006-03-13 | 2007-09-19 | Siegfried Ltd. | Di-polymer protein conjugates and processes for their preparation |
US20090117077A1 (en) * | 2006-05-12 | 2009-05-07 | Dong-A Pharm. Co., Ltd. | Polyethylene glycol-interferon alpha conjugate |
JP2008069073A (ja) * | 2006-09-12 | 2008-03-27 | Yokohama Tlo Co Ltd | ラクトフェリン複合体及びその製造方法 |
KR101079993B1 (ko) * | 2006-11-17 | 2011-11-04 | 동아제약주식회사 | 폴리에틸렌글리콜 과립구 콜로니 자극인자 접합체 |
CL2008002399A1 (es) | 2007-08-16 | 2009-01-02 | Pharmaessentia Corp | Conjugado sustancialmente puro que posee una porcion polimerica, una porcion proteica (interferon alfa 2b) y un ligante alifatico de 1 a 10 atomos de carbono, util en el tratamiento de las hepatitis b o c. |
EP2300501B1 (en) * | 2008-07-23 | 2014-08-20 | Hanmi Science Co., Ltd. | A polypeptide complex comprising non-peptidyl polymer having three functional ends |
EA020347B1 (ru) | 2008-07-31 | 2014-10-30 | Фармаиссэншиа Корп. | Пептид-полимерные конъюгаты |
US8535655B2 (en) | 2008-10-10 | 2013-09-17 | Polyactiva Pty Ltd. | Biodegradable polymer—bioactive moiety conjugates |
WO2010040187A1 (en) | 2008-10-10 | 2010-04-15 | The Bionic Ear Institute | Polymer-bioactive agent conjugates |
EP2355853B1 (en) * | 2008-10-10 | 2016-12-07 | Polyactiva Pty Ltd | Biodegradable polymer - bioactive moiety conjugates |
US8680050B2 (en) | 2009-02-03 | 2014-03-25 | Amunix Operating Inc. | Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same |
BR122021021381B1 (pt) | 2009-02-03 | 2023-05-16 | Amunix Pharmaceuticals, Inc | Método de aprimoramento de uma propriedade de uma proteína biologicamente ativa |
US8703717B2 (en) | 2009-02-03 | 2014-04-22 | Amunix Operating Inc. | Growth hormone polypeptides and methods of making and using same |
US9849188B2 (en) | 2009-06-08 | 2017-12-26 | Amunix Operating Inc. | Growth hormone polypeptides and methods of making and using same |
US8841249B2 (en) | 2009-08-06 | 2014-09-23 | Novo Nordisk A/S | Growth hormones with prolonged in-vivo efficacy |
CN101831067A (zh) * | 2010-05-31 | 2010-09-15 | 王二新 | 聚乙二醇脂类缀合物及其在制备药物中的应用 |
EP2446898A1 (en) | 2010-09-30 | 2012-05-02 | Laboratorios Del. Dr. Esteve, S.A. | Use of growth hormone to enhance the immune response in immunosuppressed patients |
CN102367290B (zh) * | 2011-04-26 | 2013-05-08 | 厦门赛诺邦格生物科技有限公司 | 链官能化的多级支化聚乙二醇及其合成方法 |
WO2014110867A1 (zh) * | 2013-01-17 | 2014-07-24 | 厦门赛诺邦格生物科技有限公司 | 一种单一官能化的支化聚乙二醇及其修饰的生物相关物质 |
CN104877127B (zh) | 2015-06-23 | 2017-11-10 | 厦门赛诺邦格生物科技股份有限公司 | 一种八臂聚乙二醇衍生物、制备方法及其修饰的生物相关物质 |
MY191506A (en) | 2014-11-06 | 2022-06-28 | Pharmaessentia Corp | Dosage regimen for pegylated interferon |
US11518781B2 (en) | 2017-12-29 | 2022-12-06 | Hoffmann-La Roche Inc. | Process for providing PEGylated protein composition |
US20200362002A1 (en) * | 2017-12-29 | 2020-11-19 | Hoffmann-La Roche Inc. | Process for providing pegylated protein composition |
US20200323993A1 (en) * | 2017-12-29 | 2020-10-15 | Hoffmann-La Roche Inc. | Process for providing pegylated protein composition |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993000109A1 (en) * | 1991-06-28 | 1993-01-07 | Genentech, Inc. | Method of stimulating immune response using growth hormone |
JP3092531B2 (ja) * | 1996-11-05 | 2000-09-25 | 日本油脂株式会社 | コハク酸イミジル基置換ポリオキシアルキレン誘導体の製造方法 |
DE69838552T2 (de) * | 1997-07-14 | 2008-05-21 | Bolder Biotechnology, Inc., Louisville | Derivate des wachstumshormons und verwandte proteine |
JP3921781B2 (ja) * | 1998-02-12 | 2007-05-30 | 日本油脂株式会社 | カルボキシル基含有ポリオキシアルキレン化合物 |
EP2305804B1 (en) * | 1999-01-14 | 2015-05-06 | Bolder Biotechnology, Inc. | MonoPEGylated human growth hormone |
HUP0500997A2 (en) * | 2001-11-20 | 2007-11-28 | Pharmacia Corp | Chemically-modified human growth hormone conjugates |
ES2897470T3 (es) * | 2002-09-09 | 2022-03-01 | Nektar Therapeutics | Alcanales poliméricos solubles en agua |
JP4412461B2 (ja) * | 2002-11-20 | 2010-02-10 | 日油株式会社 | 修飾された生体関連物質、その製造方法および中間体 |
EP1581260B1 (en) * | 2002-12-31 | 2014-09-17 | Nektar Therapeutics | Polymeric reagents comprising a ketone or a related functional group |
WO2005000360A2 (en) * | 2003-05-23 | 2005-01-06 | Nektar Therapeutics Al, Corporation | Peg derivatives having an amidocarbonate linkage |
-
2005
- 2005-08-25 KR KR1020077004912A patent/KR20070042567A/ko not_active Application Discontinuation
- 2005-08-25 MX MX2007002441A patent/MX2007002441A/es unknown
- 2005-08-25 JP JP2007529040A patent/JP2008511610A/ja active Pending
- 2005-08-25 BR BRPI0515118-0A patent/BRPI0515118A/pt not_active IP Right Cessation
- 2005-08-25 WO PCT/IB2005/002939 patent/WO2006024953A2/en active Application Filing
- 2005-08-25 CA CA002577999A patent/CA2577999A1/en not_active Abandoned
- 2005-08-25 AP AP2007003919A patent/AP2007003919A0/xx unknown
- 2005-08-25 CN CNA2005800291171A patent/CN101010105A/zh active Pending
- 2005-08-25 AU AU2005278903A patent/AU2005278903A1/en not_active Abandoned
- 2005-08-25 EP EP05784225A patent/EP1789092A2/en not_active Withdrawn
- 2005-08-25 EA EA200700380A patent/EA200700380A1/ru unknown
- 2005-08-26 PE PE2005000991A patent/PE20060654A1/es not_active Application Discontinuation
- 2005-08-29 AR ARP050103612A patent/AR050851A1/es unknown
- 2005-08-29 UY UY29088A patent/UY29088A1/es not_active Application Discontinuation
- 2005-08-30 TW TW094129583A patent/TW200621291A/zh unknown
- 2005-08-30 GT GT200500235A patent/GT200500235A/es unknown
- 2005-08-30 NL NL1029828A patent/NL1029828C2/nl not_active IP Right Cessation
-
2007
- 2007-01-31 IL IL181085A patent/IL181085A0/en unknown
- 2007-02-26 CR CR8942A patent/CR8942A/es not_active Application Discontinuation
- 2007-02-27 EC EC2007007281A patent/ECSP077281A/es unknown
- 2007-02-27 TN TNP2007000078A patent/TNSN07078A1/fr unknown
- 2007-02-28 MA MA29724A patent/MA28908B1/fr unknown
- 2007-02-28 ZA ZA200701802A patent/ZA200701802B/xx unknown
- 2007-03-09 NO NO20071322A patent/NO20071322L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
CN101010105A (zh) | 2007-08-01 |
ECSP077281A (es) | 2007-03-29 |
MA28908B1 (fr) | 2007-10-01 |
AP2007003919A0 (en) | 2007-02-28 |
IL181085A0 (en) | 2007-07-04 |
MX2007002441A (es) | 2007-05-04 |
CA2577999A1 (en) | 2006-03-09 |
TW200621291A (en) | 2006-07-01 |
EP1789092A2 (en) | 2007-05-30 |
GT200500235A (es) | 2006-03-21 |
UY29088A1 (es) | 2006-03-31 |
NL1029828A1 (nl) | 2006-03-01 |
CR8942A (es) | 2007-08-16 |
ZA200701802B (en) | 2008-08-27 |
WO2006024953A2 (en) | 2006-03-09 |
JP2008511610A (ja) | 2008-04-17 |
NO20071322L (no) | 2007-05-29 |
BRPI0515118A (pt) | 2008-07-01 |
AU2005278903A1 (en) | 2006-03-09 |
AR050851A1 (es) | 2006-11-29 |
NL1029828C2 (nl) | 2006-10-20 |
KR20070042567A (ko) | 2007-04-23 |
PE20060654A1 (es) | 2006-08-12 |
WO2006024953A3 (en) | 2007-01-18 |
EA200700380A1 (ru) | 2007-10-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TNSN07078A1 (fr) | Conjugues d'hormone de croissance humaine avec un polyethyleneglycol ramifie avec du glycerol, procede pour leur preparation et methodes pour leur utilisation | |
AU2017216533B2 (en) | Improved peptide pharmaceuticals | |
EP1940452B1 (en) | Cgrp peptide antagonists and conjugates | |
AU2012255119B2 (en) | Improved peptide pharmaceuticals for insulin resistance | |
US7381707B2 (en) | Treatment of dry eye | |
AU2015289642A1 (en) | Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases | |
EP2922876A1 (en) | Improved peptide pharmaceuticals for insulin resistance | |
US10494402B2 (en) | Peptides that stimulate subcutaneous adipogenesis | |
WO2014081864A1 (en) | Improved peptide pharmaceuticals | |
TNSN07039A1 (fr) | Therapie d'association utilisant des proteines de fusion de transferrine comprenant glp-1 | |
EP1792915A3 (en) | Compounds with the biological activity of vasoactive intestinal peptide for the treatment of pulmonary and arteriolar hypertension | |
AU2015266854A2 (en) | Improved peptide pharmaceuticals for insulin resistance | |
Gourlet et al. | Interaction of lipophilic VIP derivatives with recombinant VIP1/PACAP and VIP2/PACAP receptors | |
FR2860236A1 (fr) | Peptides possedant notamment une activite anti-angiogenique et leurs applications en therapeutique | |
CN103501801A (zh) | 甲状旁腺激素类似物、其组合物和用途 | |
US20180230188A1 (en) | Peptides, compositions, and methods for stimulating subcutaneous adipogenesis | |
Arsenijevic et al. | Vasopressin-binding sites in the pig pituitary gland: competition by novel vasopressin antagonists suggests the existence of an unusual receptor subtype in the anterior lobe | |
YU48997A (sh) | Novi biološki aktivni proteini, njihove farmaceutske smeše i postupak za njihovo dobijanje | |
US9464128B2 (en) | Site-specific pegylated linear salmon calcitonin analogues | |
Bai | Subcellular distribution of proteolytic activities degrading bioactive peptides and analogues in the rat small intestinal and colonic enterocytes | |
HK1092162A1 (en) | Biologically active peptides comprising isoleucyl-valyl-threonyl- asparaginyl-threonyl-threonine (ivtntt) | |
CN112654634B (zh) | 合成肽、前药、药物组合物及用途 | |
EP1307217A2 (en) | Vip-related peptides for the treatment of skin disorders | |
US20200360466A1 (en) | Method of improving lower urinary tract symptoms | |
TH71270B (th) | อนุพันธ์เมทาสทินและการใช้ของสารเหล่านั้น |